memo - Magazine of European Medical Oncology

, Volume 5, Issue 4, pp 277–280

“Stem cell transplantation: its importance today”

Chronic myeloid leukaemia: stem cell transplantation versus new drugs

Authors

    • Centre for HaematologyImperial College London at Hammersmith Hospital, Catherine Lewis Centre
  • Joydeep Chakrabartty
    • Centre for HaematologyImperial College London at Hammersmith Hospital, Catherine Lewis Centre
  • Jane F. Apperley
    • Centre for HaematologyImperial College London at Hammersmith Hospital, Catherine Lewis Centre
short review

DOI: 10.1007/s12254-012-0042-z

Cite this article as:
Pavlu, J., Chakrabartty, J. & Apperley, J. memo (2012) 5: 277. doi:10.1007/s12254-012-0042-z
  • 97 Views

Abstract

Allogeneic stem cell transplantation (SCT) had traditionally been the first-line therapy of chronic myeloid leukaemia (CML), but the introduction of tyrosine kinase inhibitors (TKI) has caused a major change to the treatment algorithm. The majority of patients in chronic phase obtain an excellent response to these oral agents with minimal toxicity. SCT is therefore used only in a minority of patients who do not achieve adequate response to first-, second- or even third-generation agents. Patients in accelerated phase are less likely to achieve an optimal response and for patients in blast phase, SCT continues to be the only therapy with curative potential although it is now increasingly used in combination with TKI. This review discusses the place of SCT in the current therapy of CML.

Keywords

Stem cell transplantChronic myeloid leukaemiaTyrosine kinase inhibitorToxicity

Copyright information

© Springer-Verlag Wien 2012